US adults with overweight or obesity starting liraglutide, semaglutide or tirzepatide
“Accounting for censoring, 53.6% (95% CI, 53.4%-53.9%) discontinued by 1 year, and 72.2% (95% CI, 71.9%-72.4%) discontinued by 2 years.”
JAMA Netw Open, 2025 · other primary study · PMID 39888616